这是演示店铺,请务下单付款,避免造成你的财物损失。

为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!

N-[(2S)-2,3-二羟基丙基]-3-[(2-氟-4-碘苯基)氨基]-4-吡啶甲酰胺

选择性和有效的ATP非竞争性MEK1 / 2变构抑制剂。
规格或纯度: ≥98%
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
A125227-5mg
5mg 现货 Stock Image
A125227-10mg
10mg 现货 Stock Image
A125227-50mg
50mg 现货 Stock Image

基本描述

别名 MSC1936369B;AS703026
英文别名 MSC1936369B;AS-703026;AS 703026;N-[(2S)-2,3-Dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino]-4-pyridinecarboxamide
规格或纯度 ≥98%
英文名称 Pimasertib (AS-703026)
生化机理 AS703026 is a highly selective and potent noncompetitive inhibitor of MEK1 and MEK2 (IC50 = 5-11 nM).
储存温度 -20°C储存
运输条件 超低温冰袋运输
产品介绍

Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines.A potent inhibitor of MEK1 and MEK2.

Pimasertib (AS-703026) is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2 with IC50 of 5 nM-2 μM in MM cell lines.
A potent inhibitor of MEK1 and MEK2.

名称和标识符

IUPAC Name N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)pyridine-4-carboxamide
INCHI InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1
InChi Key VIUAUNHCRHHYNE-JTQLQIEISA-N
Canonical SMILES C1=CC(=C(C=C1I)F)NC2=C(C=CN=C2)C(=O)NCC(CO)O
PubChem CID 44187362
分子量 431.2

化学和物理性质

溶解性 DMSO ≥83mg/mL Water <1.2mg/mL Ethanol ≥2.6mg/mL

质检证书(COA)

质检报告(COA)

输入批号以搜索COA:

产品问答

产品问答

登录提交问题 Hover me 请先登录再提交问题
您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D et al..  (2010)  Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo..  Br J Haematol,  149  (4):  (537-49).  [PMID:20331454]
2. Yoon J, Koo KH, Choi KY.  (2011)  MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy..  Cancer Res,  71  (2):  (445-53).  [PMID:21118963]
3. Chang-Yew Leow C, Gerondakis S, Spencer A.  (2013)  MEK inhibitors as a chemotherapeutic intervention in multiple myeloma..  Blood Cancer J,  (13):  (e105).  [PMID:23524590]

计算器